Clinical Trial Update: Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions [Phase 2]

View source ↗

Summary

Phase 2 trial update of an immune checkpoint inhibitor for high-risk oral premalignant lesions (oral premalignant lesions).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Premalignant Lesions

Snippet

Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Conditions: Oral Premalignant Lesions | Phase 2 | Status: UNKNOWN